We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CXM:NYSESprinklr, Inc. Analysis

Data as of 2026-06-03 - not real-time

$5.62

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Sprinklr (CXM) is trading at $5.62, comfortably above the $4.81 support level but still below the $6.02 resistance, with the 20‑day SMA ($5.31) and 50‑day SMA ($5.44) both under the current price, indicating short‑term momentum. Technical indicators show a bullish MACD histogram (+0.08) and an RSI of 56.6, suggesting the stock is not yet overbought. However, the 200‑day SMA ($6.77) sits above the price, reflecting a longer‑term bearish bias. Volatility is high at 53% over the past 30 days, while beta is modest (0.60), implying the stock moves less than the market despite price swings. Fundamentals reveal 8.9% YoY revenue growth, a solid gross margin of 67%, and ample cash ($502M) against modest debt ($46.7M). The trailing PE of 62.4 far exceeds the industry average of 43.4, but the forward PE of 10.4 and a DCF‑derived fair value of $12.86 suggest significant upside (~50%). The company does not pay a dividend, and its cash‑rich balance sheet reduces financial risk. Recent earnings beat and positive guidance have fueled investor optimism, reflected in an “Extreme Greed” sentiment index of 92.66.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price is above immediate support but below resistance
  • Bullish MACD histogram supports near‑term upside
  • High short‑term volatility tempers aggressive buying

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth of 8.9% YoY and expanding margins
  • Forward PE of 10.4 indicates earnings acceleration
  • DCF fair value suggests ~50% upside potential

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • AI‑driven unified CX platform with strong market tailwinds
  • Robust cash position and low leverage provide financial stability
  • Strategic partnerships and expanding product suite support sustainable growth

Key Metrics & Analysis

Financial Health

Revenue Growth8.90%
Profit Margin2.67%
P/E Ratio62.4
ROE3.80%
ROA2.98%
Debt/Equity7.88
P/B Ratio2.4
Op. Cash Flow$159.2M
Free Cash Flow$142.5M
Industry P/E43.4

Technical Analysis

TrendBearish
RSI56.6
Support$4.81
Resistance$6.01
MA 20$5.31
MA 50$5.44
MA 200$6.77
MACDBullish
VolumeStable
Fear & Greed Index92.66

Valuation

Fair Value$12.86
Target Price$8.47
Upside/Downside50.69%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.60
Volatility53.12%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.